WASHINGTON — Medicaid must cover drugs that the Food and Drug Administration has approved with a lower standard of evidence through its “accelerated approval” program, the Centers for Medicare and Medicaid Services said Wednesday in a letter to states.

This announcement comes at a time when state Medicaid agencies and private insurers are trying to figure out what to do about high-priced drugs with unclear benefits. One example is Exondys 51, Sarepta’s treatment for Duchenne muscular dystrophy, which can cost $300,000 a year. Some patients have struggled to get this drug covered by Medicaid, even though Medicaid is supposed to cover all FDA approved outpatient drugs after the state program signs a pricing agreement with the company.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy